Drug Approval | August 28, 2021
DCGI approves Enzene biosimilar Denosumab for Osteoporosis
This is Enzene Biosciences third biosimilar to be approved
This is Enzene Biosciences third biosimilar to be approved
It is estimated that over 11,000 children across Europe, Middle East, and Africa are affected by achondroplasia and could be eligible for treatment with Voxzogo
The centre established by Nucleome Informatics will take up the sequencing of 5,000 Covid genomes and 500 human genomes in the coming months
This facility will integrate with existing Max hospitals and create a 2,300-bed contiguous medical hub spread over 23 acres. The first phase is to be ready by 2024
Blood samples were collected from 114 healthcare workers who received Covaxin in Chennai from February to May 2021
Roche is notifying healthcare professionals and patients in the US about this withdrawal. Patients being treated with Tecentriq for PD-L1-positive mTNBC should discuss their care with their healthcare provider
The manufacture of finished doses will commence in 2022 and at full operational capacity, the annual production is expected to exceed 100 million doses annually
The two-year donation supports the development of clinical tests for Covid-19 severity assessment and the focus on the development of simple immunoassays using single molecule counting technology
Opaganib, a leading novel small molecule investigational oral pill in development for Covid-19, is a unique host targeted, dual antiviral and anti-inflammatory drug that acts on the cause and effect of the disease
New interim data from these studies demonstrate that a booster dose of the Johnson & Johnson Covid-19 vaccine generated a rapid and robust increase in spike-binding antibodies, nine-fold higher than 28 days after the primary single-dose vaccination.
Subscribe To Our Newsletter & Stay Updated
